<SEC-DOCUMENT>0000950123-19-007197.txt : 20191108
<SEC-HEADER>0000950123-19-007197.hdr.sgml : 20191108
<ACCEPTANCE-DATETIME>20190807172624
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-19-007197
CONFORMED SUBMISSION TYPE:	DRSLTR
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20190807

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Vir Biotechnology, Inc.
		CENTRAL INDEX KEY:			0001706431
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				812730369
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRSLTR

	BUSINESS ADDRESS:	
		STREET 1:		499 ILLINOIS STREET
		STREET 2:		SUITE 500
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		415-906-4324

	MAIL ADDRESS:	
		STREET 1:		499 ILLINOIS STREET
		STREET 2:		SUITE 500
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRSLTR
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>DRSLTR</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g755217g67j71.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Laura A. Berezin</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 650 843 5128</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">lberezin@cooley.com</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">By EDGAR and courier</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>*FOIA Confidential Treatment Request* </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by Vir Biotechnology, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>in connection with Draft Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (CIK No.&nbsp;0001706431) </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August&nbsp;7, 2019 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Irene Paik </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mary Beth Breslin </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ibolya Ignat </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Angela Connell </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office of Healthcare&nbsp;&amp; Insurance </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Division of Corporation Finance </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Securities and Exchange
Commission </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100 F Street, N.E. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Washington, D.C. 20549 </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Re:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Vir Biotechnology, Inc. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Draft Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Submitted June&nbsp;27, 2019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>CIK No.&nbsp;0001706431 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Mses. Paik,
Breslin, Ignat and Connell: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On behalf of Vir Biotechnology, Inc. (&#147;<B><I>Vir</I></B>&#148; or the &#147;<B><I>Company</I></B>&#148;)
we submit this letter in response to comments received from the staff (the &#147;<B><I>Staff</I></B>&#148;) of the Securities and Exchange Commission (the &#147;<B><I>Commission</I></B>&#148;) by letter dated July&nbsp;25, 2019 (the
&#147;<B><I>Comment Letter</I></B>&#148;) with respect to the Company&#146;s Confidential Draft Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> submitted to the Commission on June&nbsp;27, 2019 (the
&#147;<B><I>DRS</I></B>&#148;). Concurrently with the submission of this response letter, the Company is submitting Amendment No.&nbsp;1 to the Company&#146;s Confidential Draft Registration Statement on Form
<FONT STYLE="white-space:nowrap">S-1</FONT> (&#147;<B><I>DRS Amendment No.</I></B><B><I></I></B><B><I>&nbsp;1</I></B>&#148;). In addition to addressing the comments raised by the Staff in its Comment Letter, the Company has included other revisions
and updates to its disclosure in DRS Amendment No.&nbsp;1. For the Staff&#146;s reference, we have included two copies of DRS Amendment No.&nbsp;1 marked to show all changes from the DRS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the commercially sensitive nature of information contained in this letter, this submission is accompanied by the Company&#146;s request
for confidential treatment for selected portions of this letter. The Company has filed a separate letter with the Office of Freedom of Information and Privacy Act Operations in connection with the confidential treatment request pursuant to Rule 83
of the Commission&#146;s Rules on Information and Requests, 17 C.F.R. &#167; 200.83. For the Staff&#146;s reference, we have enclosed a copy of the Company&#146;s letter to the Office of Freedom of Information and Privacy Act Operations as well as a
copy of this correspondence, marked to show the portions redacted from the version filed via EDGAR and for which the Company is requesting confidential treatment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the convenience of the Staff, the numbering of the paragraphs below corresponds to the numbering of the comment in the Comment Letter, the
text of which we have incorporated into this response letter for convenience in italicized type and which is followed by the Company&#146;s response. In the responses below, page number references are to DRS Amendment No.&nbsp;1. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***] = Certain confidential information contained in this document,
marked by bracketed asterisks, has been omitted and filed separately with the Securities and Exchange Commission pursuant to 17 CFR &#167;200.83. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Cooley LLP&nbsp;&nbsp;&nbsp;&nbsp;3175 Hanover Street&nbsp;&nbsp;&nbsp;&nbsp;Palo Alto, CA&nbsp;&nbsp;&nbsp;&nbsp;94304-1130 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">t: (650) 843-5000&nbsp;&nbsp;f: (650) 849-7400&nbsp;&nbsp;cooley.com </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g755217g67j71.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August 7, 2019 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 2
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Draft Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> submitted June&nbsp;27,
2019 </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Prospectus Summary </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Our Development
Pipeline, page 2 </U></I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Please revise the pipeline chart to remove the dashed arrow indicating a planned combination trial expected
to commence in Phase 2 in 2020 or to identify the immunomodulatory agent(s) that will be tested in combination with <FONT STYLE="white-space:nowrap">VIR-2218.</FONT> To the extent you have not identified the immunomodulatory agent(s) or the
immunomodulatory agent has not received regulatory approval, it is premature to include this combination therapy in your pipeline chart.</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>In response to the Staff&#146;s comment, the Company has revised the disclosure on pages 2, 75, 94 and 108 of DRS Amendment
No.&nbsp;1 to remove the dashed arrow from the pipeline chart. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Implications of Being an Emerging Growth Company, page 5 </U></I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Please supplementally provide us with copies of all written communications, as defined in Rule 405 under the
Securities Act, that you, or anyone authorized to do so on your behalf, present to potential investors in reliance on Section</I><I></I><I>&nbsp;5(d) of the Securities Act, whether or not they retain copies of the communications</I>.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>In response to the Staff&#146;s comment, the Company advises the Staff that it has commenced
&#147;testing the waters&#148; meetings with potential investors. Accordingly, the Company is supplementally providing to the Staff copies of the presentations that the Company has used in these meetings with qualified institutional buyers or
institutional accredited investors. The Company further advises the Staff that it will supplementally provide the Staff with copies of any additional written communications of the type referenced in the Staff&#146;s comment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Use of Proceeds, page 65 </U></I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Please revise your disclosure to clarify whether you will be able to complete the <FONT
STYLE="white-space:nowrap">VIR-2218</FONT> Phase 1/2 clinical trial with the net proceeds from the offering, together with existing cash, cash equivalents and short-term investments. If any material amounts of other funds are necessary, please
disclose the amount of funds needed to complete the Phase 1/2 clinical trial</I>.<I> Refer to Instruction 3 to Item 504 of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT></I> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>In response to the Staff&#146;s comment, the Company has revised the disclosure on pages 7 and 65 of DRS Amendment No.&nbsp;1
to clarify that it expects to be able to complete the <FONT STYLE="white-space:nowrap">VIR-2218</FONT> Phase 1/2 clinical trial with the net proceeds from the offering, together with existing cash, cash equivalents and short-term investments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Results of Operations </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Comparison of the Years Ended
December&nbsp;31, 2017 and 2018 </U></I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Research and Development Expenses, page 85 </U></I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Please revise to disclose your research and development expenses for each period by product candidate. If
such costs are not tracked by product candidate, please disclose that fact.</I> </P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***] = Certain confidential information contained in this document, marked by bracketed asterisks, has been omitted and filed separately
with the Securities and Exchange Commission pursuant to 17 CFR &#167;200.83. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Cooley LLP&nbsp;&nbsp;&nbsp;&nbsp;3175 Hanover
Street&nbsp;&nbsp;&nbsp;&nbsp;Palo Alto, CA&nbsp;&nbsp;&nbsp;&nbsp;94304-1130 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">t: (650) 843-5000&nbsp;&nbsp;f: (650)
849-7400&nbsp;&nbsp;cooley.com </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g755217g67j71.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August 7, 2019 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 3
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>In response to the Staff&#146;s comment, the Company has revised the
disclosure on page 82 of DRS Amendment No.&nbsp;1 to disclose that it does not track research and development expenses by product candidate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Critical
Accounting Polices and Estimates </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Stock-Based Compensation, page 90 </U></I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Once you have an estimated offering price or range, please explain to us how you determined the fair value
of the common stock underlying your equity issuances, and the reasons for any differences between the recent valuations of your common stock leading up to the IPO and the estimated offering price. This information will help facilitate our review of
your accounting for equity issuances including stock compensation and beneficial conversion features.</I> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response:
</B>The Company respectfully acknowledges the Staff&#146;s comment and will supplementally provide the requested information once the estimated offering price range has been determined. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Business </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Antibody Platform, page 98 </U></I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>We note your disclosure that anti-Ebola virus mAb114 was identified by your scientists using your technology
in collaboration with the NIH and others and that it is currently being developed by Ridgeback Biotherapeutics LP and the NIH. Please tell us how Ridgeback Biotherapeutics LP and the NIH attained rights to develop mAb114 and why you are not involved
in the development of the product candidate.</I> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>The Company acknowledges the Staff&#146;s comments,
and advises the Staff that the Company&#146;s subsidiary, Humabs BioMed SA (&#147;<B><I>Humabs</I></B>&#148;), identified mAb114 in collaboration with the National Institute of Allergy and Infectious Diseases, an institute of the National Institutes
of Health (collectively, the &#147;<B><I>NIH</I></B>&#148;), the Institute for Research in Biomedicine and other third parties. Humabs determined not to pursue a sublicense opportunity to develop mAb114 and it granted an exclusive license, with the
right to sublicense, as to Humabs&#146; rights in the intellectual property to the NIH (other than rights Humabs retained for research purposes). Thereafter, the NIH entered into an agreement with Ridgeback Biotherapeutics LP regarding the
development of mAb114. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Development Programs, page 108 </U></I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>We note your disclosure on pages 119 and 120 that the manufacture and development of VIR</I><I><FONT
STYLE="white-space:nowrap">-1111</FONT> for HIV and <FONT STYLE="white-space:nowrap">VIR-2020</FONT> for TB, respectively, are funded by the Bill</I><I></I><I>&nbsp;&amp; Melinda Gates Foundation. Noting your disclosure on page 129 that the grant
agreements for your HIV and TB programs expire on June</I><I></I><I>&nbsp;30, 2020 and your disclosure on page 65 that you expect your current grants will fund the manufacture and &#147;early clinical development of
<FONT STYLE="white-space:nowrap">VIR-1111</FONT> and <FONT STYLE="white-space:nowrap">VIR-2020,&#148;</FONT> please revise your disclosure to clarify whether the Bill</I><I></I><I>&nbsp;&amp; Melinda Gates Foundation grants will fund the development
of <FONT STYLE="white-space:nowrap">VIR-1111</FONT> and <FONT STYLE="white-space:nowrap">VIR-2020</FONT> through regulatory approval.</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>In response to the Staff&#146;s comment, the Company has revised the disclosure on pages 103, 119 and 120 of DRS Amendment
No.&nbsp;1 to clarify that it expects that the current grants from the Bill&nbsp;&amp; Melinda Gates Foundation will fund the early clinical development of <FONT STYLE="white-space:nowrap">VIR-1111</FONT> and
<FONT STYLE="white-space:nowrap">VIR-2020.</FONT> </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***] = Certain
confidential information contained in this document, marked by bracketed asterisks, has been omitted and filed separately with the Securities and Exchange Commission pursuant to 17 CFR &#167;200.83. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Cooley LLP&nbsp;&nbsp;&nbsp;&nbsp;3175 Hanover Street&nbsp;&nbsp;&nbsp;&nbsp;Palo Alto, CA&nbsp;&nbsp;&nbsp;&nbsp;94304-1130 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">t: (650) 843-5000&nbsp;&nbsp;f: (650) 849-7400&nbsp;&nbsp;cooley.com </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g755217g67j71.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August 7, 2019 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 4
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Functional Cure for HBV, page 108 </U></I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>We note your disclosure on page 109 that initial data demonstrate an approximately <FONT
STYLE="white-space:nowrap">30-fold</FONT> reduction in HBsAg at Week 12 in the three patients who have received two 50 mg doses of <FONT STYLE="white-space:nowrap">VIR-2218.</FONT> We also note that according to your chart on page 111, the trial
design calls for four chronic HBV patients in the 50 mg x 2 cohort. Given your statement on page 112 that Part B chronic HBV patients in the 50 mg cohort have completed dosing, please revise your disclosure to clarify whether a fourth patient has
completed dosing, and if so, describe the data collected to date. Furthermore, where you discuss the results of this trial in the Summary, please expand to also disclose the size of the trial.</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>In response to the Staff&#146;s comment, the Company has revised the disclosure on page 109 and 111&#150;112 of DRS Amendment
No.&nbsp;1. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Vaccine for HIV Prophylaxis, page 117 </U></I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>We note that <FONT STYLE="white-space:nowrap">VIR-1111</FONT> is a proof of concept vaccine and that changes
to the vaccine antigen from HIV will be required before subsequent phases of clinical development. Please expand your disclosure to discuss how changes to the vaccine antigen may impact the timing of regulatory approval of this product
candidate.</I> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>In response to the Staff&#146;s comment, the Company has revised the disclosure on page
118 of DRS Amendment No.&nbsp;1. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Our Collaboration, License and Grant Agreements, page 120 </U></I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Please revise your description of each applicable agreement in this section to disclose when the patents
underlying the royalty terms are expected to expire and to quantify the &#147;specified number of years&#148; portion of the duration of royalty obligations. Please note that we consider the royalty term to be a material term of an agreement that
should be disclosed in the registration statement. In addition, we note that your disclosure currently states that the upper range of some of the royalty obligations is in the &#147;low double-digits.&#148; Please revise your disclosure to provide a
range that does not exceed ten percent (e.g., between twenty and thirty percent).</I> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>In response to
the Staff&#146;s comment, the Company has revised the disclosure on pages 77&#150;78, 121&#150;127 and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">F-25&#150;F-26</FONT></FONT> of DRS Amendment No.&nbsp;1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In response to the Staff&#146;s portion of comment related to the disclosure of when the patents underlying the royalty terms of each
applicable agreement are expected to expire, the Company respectfully advises the Staff that intellectual property licensed under each applicable agreement is still evolving and under development, and the Company (in collaboration with its third
parties) expects to continue to file patents and patent applications under each applicable agreement. Given that such intellectual property rights are expected to continue to evolve and develop, the Company believes that such disclosure would not
accurately reflect the anticipated royalty terms, would not materially enhance an investor&#146;s understanding of the applicable agreements and may be potentially misleading. Furthermore, the Company believes that its disclosure of the
&#147;specified number of years&#148; portion of the duration of royalty obligations, as disclosed on pages 121&#150;127 and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">F-25&#150;F-26</FONT></FONT> of DRS Amendment No.&nbsp;1,
will provide investors with more useful, current and accurate information about the royalty terms under the applicable agreements. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***] = Certain confidential information contained in this document, marked by bracketed asterisks, has been omitted and filed separately
with the Securities and Exchange Commission pursuant to 17 CFR &#167;200.83. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Cooley LLP&nbsp;&nbsp;&nbsp;&nbsp;3175 Hanover
Street&nbsp;&nbsp;&nbsp;&nbsp;Palo Alto, CA&nbsp;&nbsp;&nbsp;&nbsp;94304-1130 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">t: (650) 843-5000&nbsp;&nbsp;f: (650)
849-7400&nbsp;&nbsp;cooley.com </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g755217g67j71.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August 7, 2019 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 5
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>We note your disclosure regarding the Visterra Agreement on page
<FONT STYLE="white-space:nowrap">F-27.</FONT> Please disclose the material terms of this agreement, including the intellectual property and technology licensed, rights and obligations of the parties, milestone payment and royalty obligations and
termination provision and file the agreement as an exhibit to the registration statement. Alternatively, please tell us why you do not believe this is required. See Item 601(b)(10) of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT></I>
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>The Company acknowledges the Staff&#146;s comments and advises the Staff that the Company analyzes
each of its agreements for materiality when it enters into the agreement and periodically thereafter. The Company respectfully advises the Staff that it does not believe that its collaboration, license and option agreement with Visterra, Inc.
(&#147;<B><I>Visterra</I></B>&#148; and the agreement, the &#147;<B><I>Visterra Agreement</I></B>&#148;), is a material contract under Item 601(b)(10) of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> The Company&#146;s consideration of
Item 601(b)(10) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> is summarized below. [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Item 601(b)(10)(i) of Regulation <FONT
STYLE="white-space:nowrap">S-K</FONT> defines a &#147;material contract&#148; as a contract made outside of the ordinary course of business which is material to the registrant. Item 601(b)(10)(ii) of Regulation
<FONT STYLE="white-space:nowrap">S-K</FONT> states that &#147;If the contract is such as ordinarily accompanies the kind of business conducted by the registrant and its subsidiaries, it will be deemed to have been made in the ordinary course of
business and need not be filed unless it falls within one or more of the following categories, in which case it shall be filed except where immaterial in amount or significance.&#148; Because the Visterra Agreement is a license of intellectual
property rights, and the Company&#146;s business principally relates to the treatment and prevention of serious infectious diseases, the Company believes that the Visterra Agreement is the type of agreement that ordinarily accompanies its business.
Furthermore, the Company advises the Staff that the Visterra Agreement does not fall within any of the exceptions set forth in Item 601(b)(10)(ii) of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In particular, Item 601(b)(10)(ii)(B) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> clarifies that if an agreement is such as
ordinarily accompanies the kind of business conducted by the registrant, it will be deemed to be made in the ordinary course of business, and therefore not required to be filed, unless the agreement is, among other things, one &#147;upon which the
registrant&#146;s business is substantially dependent&#148; or constitutes &#147;any franchise or license or other agreement to use a patent, formula, trade secret, process or trade name upon which registrant&#146;s business depends to a material
extent.&#148; The Company respectfully submits that the Company&#146;s business is neither &#147;substantially dependent&#148; on the Visterra Agreement nor dependent on such agreement to a material extent. The Visterra Agreement is not required for
the conduct of the Company&#146;s core business, and importantly the Company [***]. The agreement does not involve a license to, or an encumbrance on, the Company&#146;s intellectual property supporting its planned product development efforts. The
licensed intellectual property is not being utilized in the development of any of the Company&#146;s five product candidates or any of the Company&#146;s technology platforms disclosed in DRS Amendment No.&nbsp;1. [***] the Visterra Agreement does
not constitute an agreement upon which the Company&#146;s business is substantially dependent or depends on to a material extent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For the
foregoing reasons, the Company believes that the Visterra Agreement is not required to be filed as a material agreement under Item 601(b)(10) of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> The Company has similarly not disclosed the
terms of the agreement in its business section. The Company advises the Staff that it will continue to evaluate in future periods whether the Visterra Agreement satisfies the definition of a &#147;material contract&#148; under Item 601(b)(10) of
Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Intellectual Property, page 133 </U></I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>For each patent that you own, license or intend to apply for, please describe the type of patent protection
represented by the application, such as composition of matter, use or process</I>. <I>In addition, please expand your disclosure regarding the patents you own relating to <FONT STYLE="white-space:nowrap">VIR-2218</FONT> to include the type of patent
protection you have, expiration dates and jurisdictions.</I> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>In response to the Staff&#146;s comment,
the Company has revised the disclosure on pages 133&#150;138 of DRS Amendment No.&nbsp;1. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***] = Certain confidential information contained in this document, marked by bracketed asterisks, has been omitted and filed separately
with the Securities and Exchange Commission pursuant to 17 CFR &#167;200.83. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Cooley LLP&nbsp;&nbsp;&nbsp;&nbsp;3175 Hanover
Street&nbsp;&nbsp;&nbsp;&nbsp;Palo Alto, CA&nbsp;&nbsp;&nbsp;&nbsp;94304-1130 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">t: (650) 843-5000&nbsp;&nbsp;f: (650)
849-7400&nbsp;&nbsp;cooley.com </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g755217g67j71.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August 7, 2019 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 6
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>General </U></I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Please provide us proofs of all graphics, visual, or photographic information you will provide in the
printed prospectus prior to its use, for example in a preliminary prospectus</I>. <I>Please note that we may have comments regarding this material.</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Response: </B>The Company advises the Staff that it does not intend to use any graphic, visual or photographic information in the
prospectus other than the Company&#146;s logo (located on the outside front and back covers of the prospectus) and tabular and other graphics that are presently included in DRS Amendment No.&nbsp;1. If the Company determines that it will include any
additional graphic, visual or photographic information, it will promptly provide such information to the Staff in an amendment or on a supplemental basis. The Company respectfully acknowledges that the Staff may have further comments regarding any
such information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp; * </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please contact me at (650) <FONT STYLE="white-space:nowrap">843-5128,</FONT> Charles Kim at (858)
<FONT STYLE="white-space:nowrap">550-6049</FONT> or Kristin VanderPas at (415) <FONT STYLE="white-space:nowrap">693-2097</FONT> with any questions or further comments regarding our response to the Staff&#146;s comment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sincerely, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Laura A. Berezin </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Laura A. Berezin </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">cc:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">George Scangos, Ph.D., Vir Biotechnology, Inc. </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Howard Horn, Chief Financial Officer, Vir Biotechnology, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Irene Pleasure, VP, Intellectual Property&nbsp;&amp; Associate General Counsel, Vir Biotechnology, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Charles S. Kim, Cooley LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Kristin VanderPas, Cooley LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Brian J. Cuneo, Latham&nbsp;&amp; Watkins LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. Shayne Kennedy, Latham&nbsp;&amp; Watkins LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Drew Capurro, Latham&nbsp;&amp; Watkins LLP </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***] = Certain confidential information contained in this document, marked by bracketed asterisks, has been omitted and filed separately
with the Securities and Exchange Commission pursuant to 17 CFR &#167;200.83. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Cooley LLP&nbsp;&nbsp;&nbsp;&nbsp;3175 Hanover
Street&nbsp;&nbsp;&nbsp;&nbsp;Palo Alto, CA&nbsp;&nbsp;&nbsp;&nbsp;94304-1130 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">t: (650) 843-5000&nbsp;&nbsp;f: (650)
849-7400&nbsp;&nbsp;cooley.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g755217g67j71.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g755217g67j71.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M&,M3V<)G.(PT>1^]'S_S.>3X/QB0%];8IW ML'\]W]*R^K>9Z3XD=M*?X_\
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MK3W>,>?+U'^Z.W\ZUA2C \K&YI7QGNRTCV7Z]RWXF\.Q>)M,2QFG>!5E$FY
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<@ H * "@ H * "@ H * "@ H * "@ H * /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
